|
Código del ensayo DF6002-001 |
|
Ensayo A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications |
|
Estado Abierto a inclusión |
|
Localización Tumoral Otros |
|
Tipo de ensayo Ensayo de Fase I |
|
Tipo de tratamiento TODOS |
|
Situación clínica Metastásico |
|
Centro |
